| From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases EH Pilkington, EJA Suys, NL Trevaskis, AK Wheatley, D Zukancic, ... Acta biomaterialia 131, 16-40, 2021 | 198 | 2021 |
| Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay SLY Teo, JJ Rennick, D Yuen, H Al-Wassiti, APR Johnston, CW Pouton Nature Communications 12 (1), 3721, 2021 | 103 | 2021 |
| The importance of poly (Ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles D Zukancic, EJA Suys, EH Pilkington, A Algarni, H Al-Wassiti, NP Truong Pharmaceutics 12 (11), 1068, 2020 | 65 | 2020 |
| In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression A Algarni, EH Pilkington, EJA Suys, H Al-Wassiti, CW Pouton, NP Truong Biomaterials Science 10 (11), 2940-2952, 2022 | 53 | 2022 |
| Delivery and expression of mRNA in the secondary lymphoid organs drive immune responses to lipid nanoparticle-mRNA vaccines after intramuscular injection A Takanashi, CW Pouton, H Al-Wassiti Molecular Pharmaceutics 20 (8), 3876-3885, 2023 | 10 | 2023 |
| The mRNA vaccine technology era and the future control of parasitic infections H You, MK Jones, CA Gordon, AE Arganda, P Cai, H Al-Wassiti, ... Clinical Microbiology Reviews 36 (1), e00241-21, 2023 | 10 | 2023 |
| Unravelling cytosolic delivery of endosomal escape peptides with a quantitative endosomal escape assay (SLEEQ) SLY Teo, JJ Rennick, D Yuen, H Al-Wassiti, APR Johnston, CW Pouton BioRxiv, 2020.08. 20.258350, 2020 | 7 | 2020 |
| Adenovirus terminal protein contains a bipartite nuclear localisation signal essential for its import into the nucleus HA Al-Wassiti, DR Thomas, KM Wagstaff, SA Fabb, DA Jans, AP Johnston, ... International Journal of Molecular Sciences 22 (7), 3310, 2021 | 6 | 2021 |
| Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose … TM Nolan, G Deliyannis, M Griffith, S Braat, LF Allen, J Audsley, ... EBioMedicine 98, 2023 | 4 | 2023 |
| Assessing the cellular toxicity of peptide inhibitors of intracellular protein-protein interactions by microinjection SB Reddiar, H Al-Wassiti, CW Pouton, CJ Nowell, MA Matthews, ... Bioorganic & Medicinal Chemistry 29, 115906, 2021 | 4 | 2021 |
| Tailored Monoacyl Poly (2-oxazoline)-and Poly (2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles X He, TJ Payne, A Takanashi, Y Fang, SD Kerai, JP Morrow, H Al-Wassiti, ... Biomacromolecules 25 (7), 4591-4603, 2024 | | 2024 |
| An LNP-mRNA vaccine provides potent immunogenicity and protection against Mycobacterium tuberculosis H Lukeman, H Al-Wassiti, SA Fabb, L Lim, T Wang, WJ Britton, M Steain, ... bioRxiv, 2024.07. 31.605765, 2024 | | 2024 |
| mRNA vaccines encoding membrane-anchored receptor-binding domains of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting HA Al-Wassiti, SA Fabb, SL Grimley, R Kochappan, JK Ho, CY Wong, ... bioRxiv, 2023.10. 04.560777, 2023 | | 2023 |
| Non-viral gene delivery agent comprising lipopeptide (LP) compounds CW Pouton, KTJ Ho, PJ White, CT Bui, N Akhtar, HA Al-wassiti US Patent 11,446,393, 2022 | | 2022 |
| mRNA therapy: a new form of gene medicine H Al-Wassiti | | 2019 |
| Towards a Non-Viral Gene Delivery Platform That Emulates the Mechanism Used to Deliver the Adenoviral Genome H Al-Wassiti, DR Thomas, S Fabb, A Johnston, C Pouton MOLECULAR THERAPY 25 (5), 324-325, 2017 | | 2017 |
| Lonafarnib is an oral medication that helps prevent the buildup of defective progerin or progerin-like protein. Menu SB Reddiar, H Al-Wassiti, CW Pouton, CJ Nowell, MG Matthews, ... | | |
| Towards A Novel Non-Viral Gene Delivery System Based On Adenovirus Genome HBALI AL-WASSITI Monash University, 0 | | |
